Massachusetts Financial Services Co. MA Decreases Stock Holdings in Merck & Co., Inc. $MRK

Massachusetts Financial Services Co. MA lowered its holdings in Merck & Co., Inc. (NYSE:MRK) by 5.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 256,668 shares of the company’s stock after selling 15,161 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Merck & Co., Inc. were worth $36,394,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in MRK. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. High Note Wealth LLC boosted its position in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

MRK has been the topic of several analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Argus upped their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Fifteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $135.50.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Phase 3 melanoma success: Moderna and Merck said their individualized mRNA vaccine, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a large Phase 3 trial. The combination significantly extended recurrence-free survival and reduced the risk of melanoma spreading compared with Keytruda alone. This represents the first positive late-stage result for a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: New growth opportunity for Keytruda: The results could expand Merck’s oncology franchise by pairing Keytruda with a mutation-targeted vaccine. The companies believe thousands of high-risk melanoma patients could eventually benefit, pending regulatory approval targeted for 2027. Similar trials are underway in lung, pancreatic, breast and other cancers. Why this mRNA cancer vaccine is raising new treatment hope
• Positive Sentiment: Strategic importance before patent expiry: A successful vaccine-Keytruda combination could help support Merck’s oncology pipeline as Keytruda’s patent protection is expected to expire later this decade. Unusually heavy call-option activity also indicated heightened bullish trading interest.
• Neutral Sentiment: Broader market support: Relief in bond markets helped lift rate-sensitive healthcare stocks generally, providing an additional supportive backdrop for Merck’s move. However, the company’s advance was primarily tied to the vaccine announcement.
• Negative Sentiment: Important uncertainties remain: The companies released topline results, while investors and analysts await complete trial data. The vaccine still requires regulatory approval, and the commercial opportunity, pricing and longer-term benefits are not yet established. Merck also faces substantial future pressure from Keytruda’s eventual loss of exclusivity.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $152.21 on Thursday. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $153.50. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $375.53 billion, a price-to-earnings ratio of 121.77, a price-to-earnings-growth ratio of 5.83 and a beta of 0.19. The business has a 50 day simple moving average of $126.86 and a 200-day simple moving average of $120.74.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the company posted $2.13 EPS. The business’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Insiders Place Their Bets

In related news, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard R. Deluca sold 20,784 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. This trade represents a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.